Senseonics (SENS: NYSE) Investor Relations Material

Overview

Medical technology firm Senseonics Holdings, Inc. is making waves with its innovative products that aim to improve the lives of people with diabetes. The company has developed and marketed continuous glucose monitoring (CGM) systems, including Eversense, Eversense XL, and Eversense E3. These implantable CGM systems use an under-the-skin sensor, a removable and rechargeable smart transmitter, and a user-friendly app to give real-time diabetes monitoring and management for up to six months. Senseonics Holdings, Inc. provides its products to healthcare providers and patients across the United States, Europe, the Middle East, and Africa via a network of distributors and strategic fulfillment partners. The company has also collaborated with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland, and continues to lead the way in diabetes management technology.